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Abstract 
Pedigree, linkage and association studies are consistent with heritable variation for complex disease, 
due to the segregation of genetic factors in families and in the population. In contrast, de novo 
mutations make only minor contributions to heritability estimates for complex traits. Nonetheless, 
some de novo variants are known to be important in disease etiology. Identification of risk-
conferring de novo variants will contribute to discovery of etiologically relevant genes and 
pathways and may help in genetic counseling. There is presently considerable interest in the role of 
such mutations in complex neuropsychiatric disease, largely driven by new whole-genome 
genotyping and sequencing technologies. An important role for large de novo copy number 
variations has been established. Recently, whole-exome sequencing has been used to extend the 
investigation of de novo variation to point mutations in protein-coding regions. Here, we consider 
several challenges for the interpretation of such mutations in the context of neuropsychiatric disease.  
 
Whole-exome studies of de novo mutations in autism, mental retardation and schizophrenia 
Nine whole-exome studies have been published to date for neuropsychiatric disorders (see Veltman 
& Brunner
1
 for an overview), all focusing on families with sporadic cases of disease (i.e. those with 
a negative family history). Autism spectrum disorders (ASD) have received most attention, with 
five independent studies
2-6
, one study has been published for mental retardation
7
 and another three 
for schizophrenia
8-10
. A tenth study reporting whole genome sequencing of both ASD and 
schizophrenia families was published while this paper was in review
11
. These studies follow others 
that focused on de novo mutations in single or multiple candidate genes (e.g. 
12
), which we do not 
consider here. The largest studies to date, for ASD, have already yielded several candidate genes, 
highlighting the promise of “de novo” experimental designs for gene discovery in neuropsychiatric 
disease. However, direct comparisons between exome studies are complicated by differences in 
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experimental design (i.e. the use of matched family controls, population controls or a theoretical 
control), definition of the targeted exome, sequencing methodology and other features, such as 
whether insertions and deletions were considered along with point mutations.  
 
The strongest evidence for an involvement of de novo mutations exists for ASD, based on the 
studies by Iossifov et al.
2
 and Sanders et al.
6
, which are the largest to date and the only studies to 
use a comprehensive sample of family controls (in the form of phenotypically discordant siblings). 
These studies, which along with O’Roak et al.5 sequenced non-overlapping sub-sets of the Simons 
Simplex Collection (SSC), showed an enrichment of de novo gene-disrupting mutations (i.e. 
nonsense, splice, frameshift) in probands compared to their unaffected siblings
2
, particularly for 
those in brain-expressed genes
6. O’Roak et al.5 used a similar approach but did not identify an 
association, perhaps due to the small size of their control sample (N=50). Xu et al.’s9,10 
schizophrenia studies are the only others to incorporate controls, in the form of healthy parent-
offspring trios. They found no difference in the de novo mutation rate in cases versus controls, but 
there was a significant enrichment of putatively functional mutations in cases. Other studies, in lieu 
of control samples, have relied on comparisons to the theoretical expectation based on previously 
reported mutation rates
3,4,7,8
, to test for an enrichment of de novo mutation in disease. Inferences 
from these studies, although supportive of a role for de novo mutations, are inconsistent, most likely 
reflecting sampling effects and methodological differences between studies. This highlights the 
value of matched control samples, and in particular family controls, in studies of de novo mutation.  
 
Two studies have demonstrated that protein products of genes harboring highly disruptive de novo 
mutations, together with previously identified ASD genes, form significant (but distinct) protein-
protein interaction networks
3,5
, providing further evidence for a role of de novo mutation in ASD. 
Iossifov et al.
2
 also showed that genes harboring disruptive mutations in ASD probands were 
strongly over-represented in the set of genes known to interact with the fragile X mental retardation 
gene product FMRP. All studies are consistent with the existence of a large number of genes for 
these disorders, and for ASD and schizophrenia, there is evidence for a correlation between paternal 
age and the number of observed de novo mutations per child
2,4-6,9,11
. This observation, together with 
evidence for a paternal bias in the origin of de novo mutations
2,3,5,11
, is consistent with an 
accumulation of mutations in the paternal germline
13
. Collectively, these findings represent solid 
evidence for a contribution from de novo protein-coding mutations in the etiology of 
neuropsychiatric disease. However, studies published to date differ widely regarding the inferred 
penetrance of identified mutations and the overall contribution of de novo variation to disease. The 
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different conclusions reflect differences of interpretation, although true differences may exist 
between disorders.  Incorrect inference regarding the pathogenicity of de novo mutations can have 
serious consequences, both for genetic counseling
14
 and in terms of misplaced investment in 
candidate genes that fail to replicate, a recurring problem in neuropsychiatric genetics. In this 
Perspective we focus on several key challenges for the interpretation of de novo designs, including 
the differentiation of risk-conferring mutations (particularly missense mutations) from those that are 
benign, the estimation of penetrance and the quantification of the relative importance of de novo 
and inherited variation. 
 
Identifying de novo protein-coding mutations conferring risk of disease 
A major challenge for the interpretation of de novo mutations in complex disease is that high levels 
of functional genetic variation have been shown to exist in the exomes of healthy individuals
15-19
. A 
typical exome harbors ~100 gene-disrupting variants, including on average 2.8 severe recessive 
disease alleles in the heterozygous state
20
, less deleterious alleles contributing to individual 
phenotype, and benign variation in redundant genes
21
. In addition, recent studies estimate that each 
person harbors ~1 de novo protein-altering mutation, both in cases and controls
11
. The standard 
deviation of this number across individuals is also ~1, so that finding two or even three de novo 
mutations in a single genome can occur by chance
6
. Furthermore, if there are up to 1000 genes that 
can contribute to the risk of, say, ASD
6
, then observing a de novo mutation in one of those genes by 
chance is ~5%, assuming a total of 20,000 genes. Consequently, the simple presence of a 
provisionally functional de novo mutation in a proband, even one predicted to have severe effects, is 
not sufficient evidence that it contributes to risk
6
, let alone that it is sufficient to cause disease. 
Claims to this effect
4,7,8,10
 should be viewed with caution.  
 
Multiple observations, either of the same mutation or of independent mutations in the same gene, 
are required to identify risk alleles or loci. The former is unlikely in exome studies for point 
mutations in complex disorders, whereas the latter is not unexpected. In theory, per gene counts of 
functional de novo mutations in cases and controls should provide a means of identifying risk genes. 
In practice, this approach has little statistical power because so many genes contribute to 
neuropsychiatric disorders that even the largest studies to date are yet to identify a gene harboring 
more than a few de novo mutations (excluding known regions of recurrent deletions/duplications 
that arise due to non-allelic homologous recombination
22,23
). Two alternative approaches to the 
interpretation of recurrent de novo mutations in single genes have been proposed. O’Roak et al.5 
compared the occurrence of multiple de novo events in CHD8, GRIN2B, LAMC3, NTNG1 and 
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SCN1A to the expected number based on each gene’s locus-specific mutation rate. Although all five 
genes were inferred to have a nominally significant excess of de novo events, only the excess in 
NTNG1 would survive correction for testing of 14,363 brain-expressed genes. This represents a 
promising approach to gene discovery, although it is important to be aware that gene-specific 
mutation rates are estimated with error (for instance, due to uncertainty in the human-chimpanzee 
divergence time used in the calculation).  
Evidence 
Sanders et al.
6
 proposed an alternative approach to the identification of genuine risk mutations, 
based on the empirical probability, across all brain-expressed genes, of observing multiple 
independent de novo point mutations in the same gene in unrelated individuals. Using simulations 
that accounted for sample size, gene size and GC content they demonstrated that two or more gene-
disrupting mutations were unlikely to be observed by chance in the same brain-expressed gene in 
unrelated probands in their study, due to the very low rate of de novo nonsense and splice site 
mutations. A single gene (SCN2A) satisfied this threshold in their study
6
, but five others (CHD8, 
DYRK1A, GRIN2B, KATNAL2, POGZ) have been identified by combining data across the four 
largest ASD studies
2,3,5,6
. A seventh gene (CUL3) has since been identified by the addition of whole 
genome data from 44 Icelandic ASD trios
11
. These are landmark findings in ASD genetics, not only 
because GWAS methodology in larger cohorts has not met with comparable success
24
 (although we 
note that ASD GWAS samples sizes have been smaller than for other neuropsychiatric disorders, 
such as schizophrenia and bipolar disorder, for which GWAS has been successful
25
), but because 
the identified mutations, with obvious functional effects in single genes, provide valuable insights 
into disease biology. 
 
An important consideration for future efforts to identify risk genes using this approach is that the 
probability of a gene harboring multiple gene-disrupting de novo mutations by chance increases 
with sample size. Simulations from Sanders et al.
6
 suggest that the probability of this occurring 
exceeds 5% in samples of greater than ~1,400 families. However, as the de novo mutation rate is 
higher in probands than siblings, the false discovery rate (FDR) for the occurrence of two gene-
disrupting de novo mutations in probands is acceptable for sample sizes in excess of 3000 families
6
. 
Clearly, the FDR will be lower still for the presence of three or more gene-disrupting mutations in 
the same brain-expressed gene. It is noteworthy, therefore, that the estimated frequency of such 
mutations in probands in the ASD candidate genes CHD8 and SCN2A was 0.33% (5 mutations in 
~1,500 cases) and 0.2% (3 mutations in ~1,500 cases), respectively
3
. This implies that as sample 
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sizes grow from hundreds to thousands of families, candidate genes will be identified by the 
presence of ≥3 de novo gene-disrupting mutations in probands.  
 
We note that the simulations of Sanders et al.
6
, upon which these inferences are based, make a 
number of assumptions that may not hold for other ASD cohorts, or for other neuropsychiatric 
disorders. For example, a key simulation parameter estimated from their data is the de novo 
mutation rate in probands. Similar studies of equivalent magnitude in schizophrenia and other 
disorders will be needed to confirm whether the approach will be more broadly successful. 
However, on current evidence in ASD, family-based exome sequencing targeting de novo gene-
disrupting mutations is a promising new paradigm for gene discovery in complex neuropsychiatric 
disease
6
. The projected yield of ASD risk genes that will be identified in the entire SSC (~2650 
ASD families) is large, ranging from ~25-50
6
 to >100
2
, depending on the total number of ASD risk 
genes and the penetrance of individual mutations.  
 
The interpretation of de novo missense mutations in disease 
In contrast to the strong signal from gene-disrupting mutations in ASD, evidence for the 
involvement of de novo missense mutations is inconsistent. Sanders et al.
6
 reported an enrichment 
of de novo missense mutations (both in isolation and in combination with gene-disrupting 
mutations) in probands compared to unaffected siblings, particularly in brain-expressed genes, 
whereas Iossifov et al.
2
 did not. Sanders et al.
6
 found no evidence that the severity of missense 
mutations, as inferred from the degree of evolutionary conservation (e.g. GERP) and other 
functional prediction methods (e.g. PolyPhen-2), either singly or in combination, was informative 
with respect to risk. O’Roak et al.5 on the other hand assumed that missense mutations in highly 
conserved positions were equivalent to gene-disrupting mutations. In the schizophrenia study by Xu 
et al.
10
, the strongest evidence for involvement of de novo mutations comes from a large excess of 
missense mutations in cases, a result that would not be expected if this class of variation did not 
play a role in disease. The role of de novo missense mutations in ASD, and more broadly in 
neuropsychiatric disease, is consequently unclear. Larger studies will be needed to resolve this 
question because those published to date are small and have limited power to detect (or conversely 
rule out) realistic contributions from de novo missense mutations
2,6
. However, given that a large 
proportion of de novo missense mutations are predicted to be mildly deleterious
26
, and that there is 
evidence for weak purifying selection on coding sequences in human populations
16,18,19
, we 
anticipate that larger family-based exome datasets in neuropsychiatric disorders will converge on a 
significant role for de novo missense mutations.  
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A number of genes have been found to harbor two de novo missense mutations in unrelated ASD 
probands, but this is not sufficient evidence to implicate them in disease. The probability of 
observing multiple independent mutations by chance is higher for missense mutations, relative to 
gene-disrupting mutations, because the mutation rate is ~20-fold higher
6
. As a consequence, the 
FDR for the presence of multiple missense mutations is strongly dependent on the sample size and 
underlying genetic model. For studies published to date, involving ~200-300 families, three 
independent missense mutations are required to implicate a gene in disease, and four are needed as 
sample size increases, depending on the total number of risk genes. That no gene has been found to 
harbor this number of de novo missense mutations may too be a consequence of inadequate sample 
size, since the effect size of missense mutations is predicted to be modest. A salient point, given the 
primacy of the mutation rate in the interpretation of recurrent de novo mutations, is that the 
assumption of a single mutation rate for missense mutations overlooks substantial fine-scale and 
context-dependent variation in the human mutation rate. The best-known example is the 10 to 20-
fold higher rate of C>T and G>A transition mutation at CpG dinucleotides
11
, which occurs because 
cytosines in CpGs are frequently methylated, and methyl-cytosines are prone to undergo 
spontaneous deanimation to thymine
27
. Other examples of mutation rate variation have also been 
described
28,29
. Given that this variation is known to exist, more sophisticated analyses that 
differentiate missense (and for that matter gene-disrupting) mutations into different classes (e.g. 
mutations in CpG verses non-CpG dinucleotides
11
) and that interpret recurrences in the context of 
the expected mutation rate for that sub-set of mutations may be insightful. Finally, gene-based 
testing in case-control exome studies may also be an efficient means of identifying risk genes on the 
basis of segregating missense variation
30,31
. Such studies benefit from a two-fold lower sequencing 
cost in comparison to family-based studies focused on de novo mutations in probands and 
unaffected siblings, although preliminary studies indicate that very large sample sizes will be 
required for success
30
. 
 
Estimating the penetrance of de novo protein-coding mutations 
The distribution of effect sizes for de novo protein-coding mutations in neuropsychiatric disorders is 
yet to be determined. The expectation is that these variants will exhibit moderate to large effect size, 
since this is the case for identified recurrent copy number variations (CNVs)
32
. Several of the 
studies mentioned in this article favor models involving highly penetrant mutations. For example 
Vissers et al.
7
 proposed that de novo point mutations of large effect, in combination with de novo 
CNVs “could explain the majority of all mental retardation cases in the population”, and Xu et al.10 
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stated that de novo mutations, including newly arisen CNVs “account for more than half of the 
sporadic cases of schizophrenia”. In ASD Iossifov et al.2 support a model in which a third or more 
of all sporadic cases harbor causal de novo mutations
33
. These statements imply that single de novo 
mutations may be sufficient to cause disease, consistent with the model of extreme genetic 
heterogeneity for complex disease advocated by some
34
. While the existence of some fully 
penetrant mutations is a possibility, particularly for mental retardation (e.g. 
35,36
), ASD (e.g. 
37
) and 
other disorders with documented monogenic forms (schizophrenia and bipolar disorder being 
prominent exceptions
25
), the suggestion that a large proportion of cases for any common 
neuropsychiatric disorder are due to highly penetrant de novo events is not consistent with empirical 
evidence of the recurrence risk (RR) to relatives
38,39
 (a point we discuss in more detail in the next 
section and Supplementary Note). More specifically, there is currently no way to determine which, 
if any, de novo protein-coding mutations are sufficient to cause disease, because no single event has 
been observed more than once. This is in contrast to documented recurrent CNVs, many of which 
have been observed in multiple cases and controls.  
 
The currently available data in ASD are sufficient for effect size estimates of broad classes of 
mutations (e.g. gene-disrupting), and are consistent with more modest average penetrance. Sanders 
et al.
6
 used data from matched family controls to demonstrate that the odds ratio (OR) for gene-
disrupting mutations relative to silent mutations in brain-expressed genes in ASD cases compared to 
unaffected siblings was 5.65 (95% CI 1.44-22.20), similar to that of documented multigenic 
CNVs
40
. Estimates for de novo missense mutations were lower (OR=2.06, 95% CI 1.10-3.85), but 
nonetheless greater than for identified common variants
24
. These estimates are likely to represent a 
mix of risk and benign mutations, and thus individual risk mutations may have larger effects
6
. 
Nonetheless, they imply that the majority of individual de novo mutations in ASD are insufficient to 
cause disease and therefore must combine with other risk factors (including inherited variation and 
environmental factors) to generate a phenotype. This is a crucial point that in some studies seems 
under-appreciated
2,7,10,33
, with important implications for the clinical application of exome 
sequencing (e.g. 
41
). The field awaits larger exome studies, including studies in multigenerational 
pedigrees, which should help to refine the distribution of effect sizes for de novo protein-coding 
mutations in ASD and other neuropsychiatric disorders. 
 
Quantifying the overall contribution of de novo protein-coding mutations to disease liability 
It is now clear that neuropsychiatric disorders are underpinned by a large number of genes
42,43
 and 
that affected individuals harbor multiple risk factors, but the relative importance of de novo and 
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inherited variation is yet to be established. The exome studies that are the focus of this article, 
although unanimous in establishing a role for de novo mutations in neuropsychiatric disorders, 
differ widely in their conclusions regarding the magnitude of this contribution. As noted above with 
respect to effect size, three studies in particular conclude that the contribution is very substantial 
and that de novo mutations (including CNVs) may account for a large proportion of all cases of 
ASD
2
, mental retardation
7
 and schizophrenia
10
. Other studies have proposed an oligogenic (or 
“multi-hit”) model in ASD4,5, whereby single de novo mutations combine with one or a few 
deleterious rare inherited variants to confer disease. In contrast, Neale et al.
3
 and Sanders et al.
6
 
favor a more limited contribution, comprising mutations with effect size similar to those of known 
CNVs in no more than 10-20% of cases. Clearly, more data will be required to resolve which of 
these models (if any) is correct, but the suggestion that de novo mutations account for a large 
proportion of the total liability for these disorders is hard to reconcile with heritability estimates that 
are consistently high (i.e. ~80% for ASD
38
 and schizophrenia
44
). A majority of de novo mutations 
are unique to a single individual, and thus will not contribute to the observed recurrence risk (RR) 
to relatives or to the estimate of heritability. Exceptions include de novo mutations originating in 
the parental germline that are shared by monozygotic (MZ) twins, or by siblings (including 
dizygotic [DZ] twins) in the case of germline mosaicism. If, as is suspected, mosaicism is relatively 
infrequent (e.g. Iossifov et al.
2
 reported the same mutation in ~1 in 50 siblings), then the effect of 
de novo variants on the estimate of heritability will be primarily through their contribution to RR of 
MZ twin pairs, and only if heritability estimates from pedigree data include MZ twins. Evidence 
from mutation-accumulation experiments, data on RR to relatives and theory suggest that this 
contribution is likely to be small, of the order of ~1% (see Supplementary Note and Supplementary 
Fig. 1). The primary contribution of de novo mutations to variance of disease risk in the population 
will usually be partitioned into the non-heritable component, and because heritability estimates for 
neuropsychiatric disorders are so high (~80%), there is a ceiling on the total contribution from de 
novo mutations (see Supplementary Note). 
 
Conclusions 
Recent family-based exome studies targeting de novo mutations in autism
2-6
, mental retardation
7
 
and schizophrenia
8-10
 are the likely forerunners of many similar efforts across the breadth of 
neuropsychiatric disease and complex disease in general. Studies considered in this article support a 
significant role for de novo protein-coding mutations in neuropsychiatric disease, particularly in 
ASD, which has been the focus of the largest studies to date. The approach established by Sanders 
et al.
6
, whereby de novo mutations are interpreted in terms of the empirical probability of observing 
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recurrent mutations in the same gene, has identified a number of promising candidate genes for 
ASD. These discoveries are particularly important because, in contrast to GWAS and the majority 
of CNV findings, they involve readily interpretable mutations in single genes, and thus provide 
immediate biological insight into disease mechanisms. Although we are mindful that equivalent 
success is yet to be demonstrated for other disorders, and that the method is dependent on 
assumptions that may not always be satisfied, it is clear that well-powered family-based exome 
sequencing studies targeting de novo mutations represent a promising new paradigm for gene 
discovery in neuropsychiatric disease. We anticipate that larger studies of this type will make an 
important contribution to progress in the field. 
 
The emerging empirical evidence on the genetic architecture of neuropsychiatric disease (and that 
of other complex diseases) from whole-exome sequencing studies (including those reviewed here), 
CNV analysis and GWAS is one of multiple genetic factors and environmental factors that jointly 
increase risk of disease. The genetic risk factors include de novo CNVs, point mutations and indels, 
rare inherited mutations and CNVs and both common and rare inherited polymorphisms. This 
spectrum of variation likely spans both protein-coding and functional non-coding regions. The latter 
are poorly represented in published exome studies but this is likely to change as the field moves 
towards whole genome sequencing and findings from the ENCODE project enable detailed 
annotation of functional non-coding elements
45
. The key challenges for the field are to clarify and 
quantify the relative importance of the different classes of variation, something that may differ 
between disorders, and to understand how they act together to cause disease. Very large studies, 
including family-based exome and/or whole genome sequencing, as well as complementary case-
control approaches, will be required to address these questions
31
. Studies that leverage 
transcriptome-wide expression data to provide insight into the functional consequences of de novo 
mutations, as has been reported for de novo CNVs in ASD
46
, are also likely to contribute.  
 
In this Perspective article we have addressed a number of challenges for the interpretation of de 
novo mutations in exome sequencing studies of neuropsychiatric disease. A clear message from 
studies to date is that the number and predicted severity of de novo mutations identified in a single 
individual is insufficient evidence for causality
6
. The burden of proof for causality for a single de 
novo mutation must be set high because incorrect inference can have serious consequences for 
individuals and their families
14
, as well as doing the field a disservice due to misplaced investment 
in candidate genes that fail to replicate. This burden of proof (‘beyond reasonable doubt’) is likely 
to be case specific, and may include knowledge of recurrent gene-disrupting de novo mutations in 
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the same gene in unrelated individuals with the same disorder, together with functional evidence 
that is consistent with both a direct effect of the mutation
46
 and the observed clinical phenotype. 
The curation of de novo protein-coding mutations and their associated phenotypes in databases, as 
has been instigated for CNVs
14,47
, will be essential to identify the genotype-phenotype correlations 
needed for robust clinical interpretation of de novo mutations in exome sequencing studies.
48
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SUPPLEMENTARY NOTE 
Quantifying the overall contribution of de novo protein-coding mutations to disease liability 
The contribution of de novo mutations to heritability estimates has received little attention. There 
are several lines of evidence to suggest that the contribution will be small. Firstly, from mutation 
accumulation experiments on complex traits across a range of model organisms, the contribution of 
new mutations to heritability has been estimated to be in the range of 0.001 and 0.01 per generation
1
. 
Secondly, a multiple variant risk model which is linear and additive on the scale of the logarithm of 
risk (i.e., multiplicative on the scale of the probability of disease, e.g. 
2,3
) predicts that log(RR) is 
linear in the degree of relationship and that log(RR) for MZ twins is twice that of full siblings 
(including DZ twins). For schizophrenia, the empirical data largely support these predictions
4,5
 
(Supplementary Fig. 1), and heritability estimates from relatives other than MZ twins do not differ 
substantially from those that include MZ twins
6
. For autism, data on recurrence risks in second 
order (and higher) relatives is lacking, but in the largest available twin studies
7
 the log(RR) of MZ 
twins is slightly less than twice that of DZ twins (e.g. 4.58 and 3.52, respectively
8
). We recognize 
that these genetic models are necessarily based upon assumptions and other genetic models can also 
fit the data. In addition, the number of MZ pairs in studies of disease with prevalence of ~1% tends 
to be low so that the sampling variance of the estimate of RR is high. Thirdly, we have performed 
theoretical calculations following Kemper et al.
9
 to assess the likely contribution of de novo point 
mutations (Vm) to the total liability (Vp) under assumptions about the number of contributing genes, 
the de novo mutation rate, the mean number of target sites for mutation per gene and the mean 
effect size. If we assume that there are 1000 genes each with 500 target sites for major (i.e. gene-
disrupting) mutation and a rate for these mutations of ~0.05 x 10
-8
 per site per generation (following 
Sanders et al.
10
), then Vm = 2 * 1000 * 500 * 0.05 x 10
-8
 * a
2
 = 5 x 10
-4
 * a
2
, with a the effect size. If 
we then assume that de novo gene-disrupting mutations have effect size similar to known de novo 
CNVs
10
 (e.g. relative risk of ~20), then log(RR) = a ~ 3, and Vm ~0.005. Based on these 
assumptions, and acknowledging that de novo germline mutations are shared by MZ but not DZ 
twins, the contribution of de novo variants with large effects to the estimate of heritability is small 
but not trivial at 2 * 0.005 = 0.01 (i.e. twice the difference between MZ and DZ similarity). These 
calculations are for gene-disrupting mutations, and it is important to recognize that other types of de 
novo mutation, including CNVs and missense mutations, will also contribute to Vm. Missense 
mutations have a higher de novo rate (~1 x 10
-8
) but the mean effect size is smaller than for gene-
disrupting mutations
10
 and so their contribution to the heritability is likely to be similar. Precise 
estimates are problematic because we do not know the total number of target sites for mutation (we 
have assumed 500,000 in the genome) or the distribution of effect sizes of new mutations. In spite 
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of this, our theoretical estimate closely matches those of Neale et al.
11
 (i.e. 1.0 - 4.6%). When taken 
together with the empirical estimates from mutation accumulation experiments and the observations 
on recurrence risk to relatives, this suggests that the contribution of de novo mutations to estimates 
of heritability is likely to be small. 
 
Quantifying the contribution of de novo mutations to variation in liability, as described above, 
contrasts sharply with measures based on the difference in mean prevalence, which are favored by 
some recent studies and which imply much larger contributions (e.g. 
12-15
). In our opinion, there is 
confusion in the literature about the definition and interpretation of these measures, which yield 
statements such as ‘the proportion of cases caused by genetic factor X’. For example, in a study of 
CNVs in children with intellectual disability (ID) and/or developmental delay (DD), Cooper et al.
12
 
state “We estimate that ~14.2% of disease in these children is caused by CNVs >400 Kb”. This bold 
statement is derived from the fact that ~25.7% of 15,767 children with ID and/or DD harbor a CNV 
of at least this size (and of population frequency <1%), compared to 11.5% of the 8,329 controls. 
The calculation of causality is then one of P(Exposure|Case) - P(Exposure|Control), 25.7 - 11.5 = 
14.2, where ‘exposure’ here is defined as having a CNV >400Kb that has a frequency <1% in the 
population. The statement of causality is, in our view, highly misleading because it assumes 
complete penetrance and ignores other risk variants harbored by the cases that may result from the 
process of the ascertainment of the case sample. The odds ratio of 2.7 or relative risk of 1.3 is the 
appropriate way to describe the contribution of CNVs >400kb in their study. These attributable 
fraction measures imply that the number of cases can be split up into categories that represent 
mutually exclusive (additive) causal factors. But for genetic factors and complex diseases, such as 
those discussed in this perspective, mutations may not be fully penetrant and hence on the risk scale 
the probability of being a case depends on multiple factors that are more likely to act 
multiplicatively than additively on that scale. Statements of causality are not justified when based 
solely on burden of a class of variants in cases versus controls.  
 
For the reasons outlined above we interpret the empirical data to favor a model in which de novo 
mutations make an important but minor contribution to the liability for neuropsychiatric disorders, 
as opposed to accounting for the majority of risk. Our position is similar to that of Neale et al.
11
, 
who concluded that the observed data on de novo protein-coding mutations was consistent with an 
overall contribution of <5% of the liability for ASD, and was not consistent with a model 
comprising a large number of pseudo-Mendelian mutations. It is worth noting that de novo 
mutations of large effect are not required to explain sporadic cases of complex neuropsychiatric 
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disease. For disorders such as schizophrenia and ASD with high heritability (e.g. ~80%) and low 
prevalence (e.g. ~1%), a high proportion of sporadic cases are expected under a purely polygenic 
model involving many contributing loci of individually small effect size
16
. Furthermore, polygenic 
variation is estimated to account for approximately one third of the genetic risk in genetic studies of 
schizophrenia in which the proportion of sporadic cases is high
17-19
. The empirical evidence, from 
multiple sources, therefore implies that de novo mutations (where present) generally combine with 
inherited variants to confer risk, and that the majority of genetic risk is explained by segregating 
variation. Recent sequencing studies have revealed a tremendous amount of rare functional 
variation in human populations
20-22
, and disease studies suggest that this variation contributes to 
individual variation
23-27
. Variants that are predicted to be functionally important are 
overwhelmingly rare
22
, and likely comprise many recently arisen (i.e. de novo) mutations that have 
survived selection and are shared by family members. We consider it likely that such variants 
collectively make a substantial contribution to the heritability, particularly for severe early-onset 
disorders (e.g. ASD, MR).  
 
A number of ASD studies mentioned in this article, although primarily focused on the role of de 
novo mutations, have tested for a higher burden of rare inherited protein-coding variation in 
probands compared to controls
10,13,28
. All three studies were negative, as was a smaller case-control 
study of idiopathic epilepsy
29
. Although these results could be interpreted as evidence that rare 
inherited variation does not contribute to disease risk, power to detect an excess of functional 
segregating protein-coding variation in cases is low given the size of the studies. There are three 
reasons for this: first, only a proportion of all functional variants will be relevant for any particular 
disorder (e.g. ~5% for ASD assuming 1000 risk genes out of a total of 20,000). Second, these 
variants will explain only a modest proportion of the overall risk, and third, the relative burden in 
cases and controls will be “muddied” by the presence of many functional variants in controls that 
predispose these individuals to any number of complex diseases other than that under investigation. 
Much larger studies, in ASD and other neuropsychiatric disorders, will be required to fully establish 
the relative contribution of de novo and inherited variation to risk of disease.  
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Supplementary Figure 1. The logarithm of the recurrence risk (RR) to relatives for schizophrenia is 
linear with respect to genetic relationship (linear regression, F(1,14) = 347.1, p = 3.12e-11, R
2
 = 
0.958), as predicted under a multiple variant risk model. Data from Lichtenstein et al.
4
 and McGue 
et al.
5
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